Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Fresenius Kabi Ltd.

Fresenius Kabi is the leading European provider of clinical nutrition and infusion therapy offering a unique and comprehensive range of products and services for both hospital and home settings. From our expertise in nutrition and infusion therapies, and through dedication to people through innovation we are committed to becoming the preferred partner worldwide for saving, treatment and caring for chronically ill patients.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

Company Details

Fresenius Kabi Ltd.
Cestrian Court, Eastgate Way, Runcorn, Cheshire, WA7 1NT
+44 (0) 1928-533 533
Contact Fresenius Kabi Ltd.
Website

 Latest Content from PMHub 

Top 10 Most Important Advisor Questions: Strengths and Weaknesses of Your Product

Videos and Podcasts | September 14, 2023 | Impetus Digital

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

Digital Opinion Leaders: The Role of Influencers in Medical Communications

White Papers and Resources | September 13, 2023 | IPG Health

There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...

Creating Hope Though Action – World Suicide Prevention Day

White Papers and Resources | September 11, 2023 | Mednet

At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'.

Medscape’s Virtual Patient Simulation Makes a Significant Impact on Real-World Treatment Selection for T2D

Press Releases | September 7, 2023 | Medscape Education

An analysis of data using Real-World Outcomes showed that a virtual patient simulation had a significant effect on real-world treatment selection for T2D. The paper, published in JMIR Medical Education,...

Top 10 Most Important Advisor Questions: Messaging and Branding

Videos and Podcasts | September 7, 2023 | Impetus Digital

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

A Rare Disease Update from Medscape Education

Press Releases | September 6, 2023 | Medscape Education

A Novel Provider Education Module to Enhance Detection of Alpha-1 Antitrypsin Deficiency

Pharma conference trends and themes in the last two years

White Papers and Resources | September 6, 2023 | Mednet

We take an in-depth look at the way Pharma conferences have changed in the last two years and how that’s impacted attendance, themes and format.

Embracing the Patient Voice Within Publications

White Papers and Resources | September 5, 2023 | OPEN Health

This whitepaper will explore multidisciplinary perspectives on how we can better engage patient communities in publications to optimize the value of their contributions, while navigating any uncertainties and reluctance from...

Navigating the nocebo effect through patient engagement is the key to setting patients up for success

White Papers and Resources | September 5, 2023 | OPEN Health

If you're interested in delving deeper into this topic and understanding how patient engagement can effectively navigate the nocebo effect, we invite you to explore our latest whitepaper.

Medscape Medical Affairs is Advancing Equity in Clinical Trials

Press Releases | September 5, 2023 | Medscape Medical Affairs

Clinical trials are not just a necessary step in bringing a new drug or device to market, but a crucial investment on the part of the developing company. By 2025,...